March 13, 2017 – Vancouver, Canada – Laguna Blends Inc. (CSE: ISOL) (OTC: LAGBF) (FSE: LB6A.F) (the “Company” or “Laguna”) is pleased to announce that it has signed a letter of Intent (LOI) to acquire 100% interest of a global Cannabis leader with unaudited annualized sales of $12,000,000 USD and adjusted EBITDA of $1,588,000 USD.
This acquisition is a major step forward in establishing Laguna as an international leader in the global cannabis industry. The Target company has an extensive portfolio of intellectual property and hemp driven CBD products including isolates, full spectrum oils, pain creams, oral sprays and other nutraceutical products. The Target company also has a medical division and is currently focusing on Latin America to develop cannabis-based pharmaceutical products.
The Hemp Business Journal estimates the total U.S. CBD market will grow to a $2.1 billion market in consumer sales by 2020 with $450 million of those sales coming from hemp-based sources.
Ray Grimm, CEO of Laguna stated, “This acquisition represents Laguna’s first foray into the rapidly growing international cannabis space. With this acquisition, through licensing deals with licensed growers and manufacturers in legal markets, Laguna is now able to capitalize on the global marketplace by utilizing existing infrastructure. The synergies of the combined entities will allow us to be more aggressive in our expansion and growth strategy and I’m very confident we will be able to create substantial shareholder value through this transaction.”
The Target company has recently acquired a leading brand of innovative cannabis infused beverages that are currently sold in California and Colorado. They also anticipate to close contracts in Canada and several other U.S. markets within the next 90 days. More information will be provided on these contracts in the coming weeks.
The CEO of the Target company stated, “As we move forward through the restructuring process of the combined entities, we will continue to focus on high growth strategies and additional acquisitions. To stay competitive amongst our competition, it is very important that we diversify our revenue verticals with new initiatives and product offerings which will add tremendous value to our current and future shareholders.”
The terms and conditions of the pending transaction are not disclosed. The transaction, which is subject to customary closing conditions and due diligence, is expected to close in Q2-2017.
About Isodiol International Inc.
Isodiol International, Inc. is the market leader in pharmaceutical grade cannabis compounds and the industry leader in manufacturing and development of consumer products. Isodiol’s nutraceutical division is the pioneer of many firsts for Hemp-derived cannabidiol (CBD), including 99% pure crystalline isolate, micro-encapsulation, and nano technology for the highest quality consumable and topical skin care products.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, seeking joint ventures and acquisitions to expand its portfolio of brands and subsidiaries and will aggressively continue International expansion into Latin America, Asia and Europe.
ON BEHALF OF THE BOARD
“Marcos Agramont” CEO & Director
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.